Investigating a genetic mutation in the p53 protein linked to cancer risk
Official title: The genetics of tumor suppression by p53
Funded at Wistar Institute · NIH-11053342 · Data updated 2026-11-12
This study is looking at a specific change in a protein called p53 that some families with a lot of cancer cases have, to see how it might affect the body's ability to prevent tumors, especially in kids with adrenal tumors, and it hopes to help us understand more about cancer risks for those with this mutation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 3, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $401,611 |
| NIH project number | 5R01CA279585-03 |
| Project ID | NIH-11053342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals from families with a history of multiple cancers, particularly those with the G334R mutation in the p53 gene.
✕Less likely to help
Patients without a family history of cancer or those who do not carry the G334R mutation may not benefit from this research.
What this research studies
This research focuses on a specific mutation in the p53 protein, known as G334R, which has been identified in families with a high incidence of various cancers, including pediatric adrenal tumors. The study aims to understand how this mutation affects the protein's ability to suppress tumor formation and its overall function in cancer biology. By analyzing tumor samples and conducting functional assays, researchers will explore the implications of this mutation on cancer predisposition and tumor suppression. Patients with this mutation may provide valuable insights into the genetic mechanisms of cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of cancer predisposition and potential new strategies for prevention and treatment.
How similar studies have gone: Previous research has shown success in understanding the role of p53 mutations in cancer, making this approach both relevant and promising.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Murphy, Maureen E. — Wistar Institute
- Study coordinator: Murphy, Maureen E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.